drugset / Trial / NCT05882357
Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age
Non-randomizedSequentialOpen-labelTreatment
Summary
This study will evaluate the pharmacokinetics (PK), safety, tolerability, pharmacodynamics (PD), and efficacy of ELX/TEZ/IVA in CF subjects 12 to less than (\<) 24 months of age.
Timeline
- Start
- 2023-06-27
- Primary completion
- 2025-09-04
- Completion
- 2025-09-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ELX/TEZ/IVA | Unknown | — | Oral |
| Subject | IVA | Unknown | — | Oral |